Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Diabetes Care

• Publication date

  2004-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIACARE.27.9.2241PMID 15333491
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.

  2001cited by this paper
• A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle.

  2001influential reference
• A potent PPARα agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscle

  2001cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes

  1999cited by this paper
• Peroxisome proliferator-activated receptors: nuclear control of metabolism.

  1999cited by this paper
• Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)

  1998cited by this paper
• Mechanism of action of fibrates on lipid and lipoprotein metabolism.

  1998cited by this paper

• Thiazolidinediones and their drug interactions involving CYP enzymes

  2018cites this paper
• Co-administration of conjugated linoleic acid and rosiglitazone increases atherogenic co-efficient and alters isoprenaline-induced vasodilatation in rats fed high fat diet.

  2018cites this paper
• NUEVOS FÁRMACOS EN DIABETES TIPO 2

  2016cites this paper
• Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone*

  2015cites this paper
• Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial

  2014cites this paper
• Rosiglitazone

  2012cites this paper
• Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin

  2011cites this paper
• PARADOxICAl S EVERE DECREASE IN HIgH-DENSITy lIPOPROTEIN CHOl ESTEROl Du E TO ROSIgl ITAz ONE-FENOFIbRATE INTERACTION

  2010cites this paper
• Fenofibrate in the treatment of dyslipidemia associated with HIV infection

  2010cites this paper
• [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].

  2010cites this paper
• High-performance Liquid Chromatographic Analysis of Pioglitazone, Gliquidone, Rosuvastatin and Simvastatin in Formulations and Human Serum

  2010cites this paper
• Combination of fenofibrate with non-statin drug regimens.

  2010cites this paper
• Paradoxical severe decrease in high-density lipoprotein cholesterol due to rosiglitazone-fenofibrate interaction.

  2010cites this paper
• [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].

  2009cites this paper
• Effectiveness and tolerability of rosiglitazone on insulin resistance and body composition in nondiabetic Thai patients undergoing continuous ambulatory peritoneal dialysis: A 12-week pilot study.

  2009cites this paper
• PPARs in Viral Disease

  2009influential citation
• Iatrogenic Severe Depression of High‐Density Lipoprotein Cholesterol

  2009cites this paper
• Il trattamento farmacologico del diabete di tipo 2 e la prevenzione cardiovascolare: cosa aggiunge liraglutide?

  2009cites this paper
• Drug Class Review: Thiazolidinediones: Final Report Update 1

  2008cites this paper
• Combination thiazolidinedione and fibrate effect on high-density lipoprotein cholesterol (HDL-C) concentration in a Veterans Affairs patient population.

  2008cites this paper
• The Treatment of Dyslipidemia—What's Left in the Pipeline?

  2008cites this paper
• The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients

  2008cites this paper
• Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate.

  2008cites this paper
• Fibrate Therapy: An Update

  2008cites this paper
• Effectiveness of lipid-lowering therapy in HIV patients

  2008cites this paper
• Paradoxical decrease in high density lipoprotein-cholesterol associated with statin and fenofibrate combination therapy:

  2007cites this paper
• HIV-associated dyslipidaemia: pathogenesis and treatment.

  2007cites this paper
• Effects of Thiazolidinediones on Serum Lipoproteins

  2007cites this paper
• Paradoxical HDL‐C reduction during rosiglitazone and fibrate treatment

  2007cites this paper
• Severe acquired (secondary) high-density lipoprotein deficiency.

  2007cites this paper
• The effect of dual PPAR α/γ stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients

  2006cites this paper
• The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

  2006cites this paper
• Long‐term treatment experience in a subject with Dunnigan‐type familial partial lipodystrophy: efficacy of rosiglitazone

  2005cites this paper
• Thiazolidinediones and lowered HDL cholesterol.

  2005cites this paper
• Current literature in diabetes.

  2005cites this paper
• Burden of type 2 diabetes in young Korean adults owing to obesity.

  2005cites this paper